Professor Bob Taylor
Dr Bob Taylor works on drug trials for vivax and falciparum malaria. In contrast with falciparum malaria, vivax malaria can relapse from dormant stage parasites in the patient’s liver. Primaquine is currently the only available drug to prevent relapse infections but can cause severe haemolysis in patients with reduced G6PD activity. Dr Taylor's research aims to determine the most effective and safest way to radically cure vivax malaria.
Primaquine for vivax and falciparum malaria
Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.
Taylor WR. et al, (2023), The Lancet Infectious Diseases, 23, 471 - 483
Rahimi BA. et al, (2022), Transactions of the Royal Society of Tropical Medicine and Hygiene, 116, 1181 - 1190
(2022), New England Journal of Medicine, 387, 282 - 283
Ghatee MA. et al, (2022), Transboundary and emerging diseases, 69, e547 - e553
Ziaee M. et al, (2022), Indian journal of medical microbiology, 40, 451 - 454